About OKYO OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ...

Chemotherapy appears to activate a stress-sensing system inside immune cells. According to new research from Weill Cornell Medicine and Wake Forest ...

Researchers discovered that chemotherapy can accidentally trigger a stress alarm in immune cells, causing inflammation that ...

Chemotherapy activates a stress sensor in immune cells, triggering inflammation and nerve damage, which may help explain why ...

OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with ...

NMNAT2 is a key protein required for axon integrity whose rapid depletion following axon injury triggers Wallerian ...

Abstract: Clinical trials previously demonstrated the notable capacity to elicit visual percepts in individuals with visual impairments caused by retinal diseases by electrically stimulating the ...

For the freshest news, join The Borneo Post's Telegram Channel and The Borneo Post on Newswav.